Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial-MedSci.cn

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Zhang, P; Zhang, QY; Tong, ZS; Sun, T; Li, W; Ouyang, QC; Hu, XC; Cheng, Y; Yan, M; Pan, YY; Teng, YE; Yan, X; Wang, Y; Xie, WM; Zeng, XH; Wang, XJ; Hu, CL; Geng, CZ; Zhang, HW; Li, WX; Wu, XH; Zhong, JC; Xu, JW; Shi, YX; Wei, WH; Bayaxi, N; Zhu, XY; Xu, BH

Xu, BH (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing 100021, Peoples R China.

Abstract

Background Adding CDK4/6 inhibitor dalpiciclib to fulvestrant significantly prolonged progression-free survival in patients with hormone receptor-posi......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

科室

工具

服务